Company Profile For Osiris Therapeutics Inc

Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company, focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The Company’s principal biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Its pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee. In August 2009, the Company announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures.

BRIEF: For the six months ended 30 June 2009, Osiris Therapeutics, Inc.'s revenues totaled $23.2M, up from $2.9M. Net loss from cont. ops. fell 56% to $16.5M. Revenues reflects agreement with Genzyme, agreement with JDRF, and contract with DoD to develop Prochymal. Net loss was partially offset by increased res. & dev. exp., higher gen. & admin. exp. The Co. is a stem cell therapeutic Co. focused on developing & marketing products.

Osiris Therapeutics Inc
7015 Albert Einstein Drive
Columbia   MD   21046
P: +1443.5451800
F: +1443.5451701

158